Shibo Jiang
2 S.J.
Lindsley F. Kimball Research Institute
New York Blood Center
New York
USA
Name/email consistency: high
- Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination. Cai, L., Pan, C., Xu, L., Shui, Y., Liu, K., Jiang, S. FASEB J. (2012)
- Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. Jiang, S., Tala, S.R., Lu, H., Abo-Dya, N.E., Avan, I., Gyanda, K., Lu, L., Katritzky, A.R., Debnath, A.K. J. Med. Chem. (2011)
- SARS vaccine development. Jiang, S., He, Y., Liu, S. Emerging Infect. Dis. (2005)
- N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., Debnath, A.K. Antimicrob. Agents Chemother. (2004)
